Deregulation of metabolic pathways has been readily accepted as part of the revised hallmarks of cancer, where cancer cells are able to regulate their metabolism to provide energy and cellular building blocks required for growth ([@bib13]). Many cancer cells are highly reliant on amino acids for their growth where endogenous synthesis may not provide the rapidly proliferating cells with sufficient nutrients for nuclear biosynthesis. There is also increasing evidence that oncogenes and/or tumour-suppressor genes can reprogram tumour cell metabolism including the direct regulation of the glutamine (Gln)--proline (Pro) regulatory axis by MYC and p53 ([@bib11]; [@bib15]; [@bib29]). This axis is the most important metabolic pathway in tumours after glucose primarily as Gln is used to replenish the tricarboxylic acid (TCA) cycle and supplies carbon and nitrogen for synthesis of nucleotides, amino acids and glutathione. Indeed, some solid tumours have Gln-dependent cell growth or 'glutamine addiction' ([@bib34]).

Glutamine is a non-essential amino acid synthesised by glutamine synthetase (GS) from glutamate and ammonia. Its utilisation, via reductive carboxylation, is necessary for sustained proliferation/survival and is linked with resistance to certain drugs ([@bib2]). A further role for Gln in cancer cell protein translation stems from observations that a master regulator of protein translation, rapamycin complex 1 (mTORC1), which regulates cell growth and protein translation, is also responsive to Gln levels ([@bib6]). In breast cancer (BC), high-grade highly proliferative tumours such as the triple negative (TN), have higher levels of glutamate and glutaminase (GLS) together with low levels of Gln than low-grade tumours and normal breast epithelium ([@bib4]; [@bib12]; [@bib17]). Metabolic profiles of BC show glutaminolysis metabolism as a key pathway discriminating between TN and oestrogen receptor (ER)+ tumours ([@bib5]). The CB-839 small-molecule selective inhibitor of GLS, which has anti-tumour activity in TNBC cell lines is currently being tested in phase I clinical trials (NCT02071862) ([@bib12]).

Glutamine is converted to glutamate by GLS before entering the TCA cycle as a precursor to α-ketoglutarate, an important energy source which is synthesised by glutamate dehydrogenase. However, glutamate can also be converted into Pro via the enzymes pyrroline-5-carboxylate synthetase (ALDH18A1) and pyrroline-5-carboxylate reductase 1 (PYCR1), which subsequently produces NADP used to fuel the breakdown of glucose by glycolysis ([@bib23]; [@bib28]) ([Figure 1](#fig1){ref-type="fig"}). ALDH18A1 is responsible for reducing glutamate to Gln semialdehyde; a crucial step in the *de novo* biosynthesis of Pro.

With renewed interest in oncometabolism, metabolic enzymes are increasingly targeted to improve therapeutic efficacy and reduce resistance. We therefore hypothesised that the Pro--Gln axis is a key metabolic pathway regulated by MYC in BC particularly as we have recently showed Pro dehydrogenase (PRODH) to be down regulated ([@bib11]). This pathway could be used as a potential therapeutic target particularly as the pleotropic MYC has so far proved ineffective.

The aim of this study was to conduct a comprehensive genomic, transcriptomic and proteomic analysis of the Gln--Pro regulatory axis in the molecular subtypes of BC and their associations with MYC. More specifically, we aim to determine GLS, ALDH18A1 and PYCR1 gene copy number and gene expression; together with its protein expression, in large well-characterised annotated cohorts of BC to determine their biological, clinicopathological and prognostic value in the different molecular classes with particular interest in the highly proliferative aggressive subgroups as potential therapeutic targets.

Materials and methods
=====================

*Gln--Pro* enzymes copy number and gene expression
--------------------------------------------------

*PYCR1, ALDH18A1, GLS and MYC* copy number and gene expression were evaluated in a cohort of 1980 BC samples using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort ([@bib7]). METABRIC provides data on genomic and transcriptomic profiling of BC using the Affymetrix SNP 6.0 and Illumina HT-12 v3 platforms, respectively. In addition, *TP53* mutational profiling was performed. Detailed description of the experimental assays and analytical methods used were described previously. In this cohort, patients with ER+ and/or lymph node negative tumours did not receive adjuvant chemotherapy, while those with ER− and/or lymph node positive tumours received adjuvant chemotherapy. Breast cancer-specific survival is defined as the time (in months) from the date of primary surgery to the date of BC-related death.

Gln--Pro enzymes protein expression
-----------------------------------

Immunohistochemistry was conducted for PYCR1, ALDH18A1 and GLS using a large cohort of patients comprising a well-characterised consecutive series of early stage (TNM stage I--III excluding T3 and T4 tumours) sporadic primary operable invasive BC. Patients (age ⩽70 years) were enroled into the Nottingham Tenovus Primary Breast Carcinoma Series, presented at Nottingham City Hospital between 1989 and 1998 (*n*=1837) and managed in accordance to uniform protocol. Patients' clinical history, tumour characteristics, information on therapy and outcomes are prospectively maintained. Outcome data were collected on a prospective basis.

Primary antibody specificity (ALDH18A1 1 : 250 (HPA012604, Sigma-Aldrich, UK), GLS 1 : 1000 (EP7212, Abcam, UK) PYCR1 1 : 250 (HPA047660, Sigma-Aldrich, UK) was validated by western blotting using MCF7, MDA-MB-231 and SKBR3 human BC cell lines (American Type Culture Collection; Rockville, MD, USA). Proteins were detected using IRDye 800CW and 680RD fluorescent secondary antibodies (1 : 15 000 dilution. 926-32213 and 926-68072, LI-COR Biosciences) and visualised using the Odyssey Fc with Image Studio 4.0 (LI-COR Biosciences). Anti-β-actin primary antibody (Sigma-Aldrich) was used as a loading control (1 : 5000). Specific bands were observed at the correct molecular weights for ALDH18A1 (87 kDa), GLS (73, 65 kDa) and PYCR1 (36 kDa). An additional 55 kDa band was observed for GLS and a 28 kDa band for PYCR1, which represent alternate isoforms of the proteins.

Tissue arrays and immunohistochemistry
--------------------------------------

Tumour samples, 0.6 mm cores, were arrayed as previously described ([@bib1]). Immunohistochemical staining was performed on 4 μm thick sections using the Novolink polymer detection system (Leica Biosystems, RE7150-K), and following the manufacturer's protocol. Primary antibodies for PYCR1, ALDH18A1 and GLS were diluted at 1 : 50 in Leica antibody diluent (RE7133). Negative (omission of primary antibody) and positive controls were included according to manufacturer's data sheet.

Stained TMA sections were scored using high-resolution digital images (NanoZoomer; Hamamatsu Photonics, Welwyn Garden City, UK) at × 20 magnification. Staining was assessed using the semi-quantitative, modified histochemical score (H-score), which evaluates both the intensity of staining and the percentage of stained cells resulting in a final score of 0--300 ([@bib8]). For intensity, a score index of 0, 1, 2, and 3 corresponding to negative, weak, moderate, and strong was used and the percentage of positive cells for each intensity was estimated subjectively. Dichotomisation of PYCR1, ALDH18A1 and GLS protein expression was determined using the median H-score. All cores were scored by NJ or HC and a pathologist (MA), blinded from the scores and the clinical data, scored 10% of cores for inter-observer concordance. There was high inter and intra-observer concordance between the scorers (Kappa score ⩾0.6).

Immunohistochemical staining and dichotomisation of other biomarkers included in this study were as per previous publications ([@bib11]). Oestrogen receptor (ER) and PgR positivity was defined as ⩾1% staining. Immunoreactivity of human epidermal growth factor receptor (HER2) in TMA cores was scored using standard HercepTest guidelines (Dako). Chromogenic *in situ* hybridisation (CISH) was used to quantify HER2 gene amplification in borderline cases using the HER2 FISH pharmDx plus HER2 CISH pharmDx kit (Dako) and was assessed according to the American Society of Clinical Oncology guidelines. Breast cancer molecular subtypes were defined based on the IHC profile as: Luminal A: ER+/HER2− low proliferation (Ki67\<10%), Luminal B: ER+/HER2− high proliferation (Ki67⩾10%), HER2-positive class: HER2+ regardless of ER status, TN: ER−, PgR− and HER2−. Basal phenotype was defined as those tumours expressing cytokeratin (Ck) 5/6, and/or Ck14 and/or Ck17.

Cluster analysis
----------------

The partitioning around medoids (PAM) algorithm (also known as k-medoids algorithm) was used to cluster tumours based on gene and protein expression of the Gln--Pro enzymes as previously described ([@bib31]). A number of cluster validity indices were used to determine the best number of clusters as the explicit input parameter to the PAM algorithm ([@bib31]).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 21.0 statistical software (SPSS Inc., Chicago, IL, USA). Univariate and multivariate analyses were performed by *χ*^2^-test, Log rank and Cox regression analysis, respectively. One way ANOVA (Tukey) and Spearman's correlation coefficient were used for continuous data. Survival curves were analysed by Kaplan--Meier. A *P*-value \<0.05 was considered significant. This study complied with reporting recommendations for tumour marker prognostic studies (REMARK) criteria ([@bib25]).

Ethics
------

This study was approved by the Nottingham Research Ethics Committee 2 under the title 'Development of a molecular genetic classification of breast cancer'. All samples from Nottingham used in this study were pseudo-anonymised and collected prior to 2006 and therefore under the Human Tissue Act informed patient consent was not needed. Release of data was also pseudo-anonymised as per Human Tissue Act regulations.

Results
=======

Gln--Pro regulatory axis expression in breast cancer
----------------------------------------------------

Gain of *PYCR1* copy number primarily occurred in Luminal B tumours with 116 out of 257 (45%) of all gains occurring ([Table 1](#tbl1){ref-type="table"}, *P*\<0.001). Expression of *PYCR1* mRNA was significantly higher in Luminal B tumours compared with Luminal A tumours, and high expression was also observed with HER2+ and Basal/TN subtypes ([Figure 2A](#fig2){ref-type="fig"}, *P*\<0.001). However there was no association observed between PYCR1 protein expression and molecular classes ([Figure 2B](#fig2){ref-type="fig"}, *P*=0.118).

Within the molecular classes, high *ALDH18A1* mRNA was associated with HER2+ tumours although there was no difference observed with mRNA levels between Luminal A and Luminal B tumours ([Figure 2C](#fig2){ref-type="fig"}, *P*\<0.001). Copy number gain of *ALDH18A1* was associated with basal tumours ([Table 1](#tbl1){ref-type="table"}, *P*\<0.001). In contrast, high ALDH18A1 protein expression was seen in the ER+/HER2− high proliferation class compared with ER+/HER2− low proliferation tumours (*P*=0.030); however significance was not observed with all molecular classes ([Figure 2D](#fig2){ref-type="fig"}; *P*=0.079).

High copy number gain of *GLS* ([Table 1](#tbl1){ref-type="table"}), GLS mRNA ([Figure 2E](#fig2){ref-type="fig"}) and protein ([Figure 2F](#fig2){ref-type="fig"}) were all significantly associated with basal/TN subtypes (*P*\<0.001). Lower *GLS* mRNA expression was seen in Luminal B tumours compared with Luminal A and the other molecular subtypes ([Figure 2E](#fig2){ref-type="fig"}; *P*\<0.001). In contrast, higher protein expression of GLS was seen in ER+/HER2− high proliferation compared with those classified as ER+/HER2− low proliferation ([Figure 2F](#fig2){ref-type="fig"}; *P*=0.022), where highest expression was seen in the TN tumours (*P*\<0.001).

Gln--Pro regulatory axis confers poor prognosis in Luminal B breast cancer
--------------------------------------------------------------------------

Breast tumours were further clustered based on the comparison of several indices comparing the gene expression of the Gln--Pro enzymes. These were characterised as follows: Cluster 1 (*GLS*^−^/*ALDH18A1*^+^/*PYCR1*^+^), Cluster 2 (*GLS*^+^/*ALDH18A1*^+^/*PYCR1*^+^) and Cluster 3 (*GLS*^+^/A*LDH18A1*^−^/*PYCR1*^−^) ([Figure 3A](#fig3){ref-type="fig"}). The clusters were significantly associated with molecular subtypes of BC, where Cluster 1 were predominately Luminal B and HER2+ tumours, Cluster 2 were associated with basal/HER2+ tumours and Cluster 3 were primarily Luminal A and normal subtypes ([Table 2](#tbl2){ref-type="table"}). With respect to patient outcome, Cluster 1 tumours had the worst survival compared with Cluster 2, which had moderate outcome and Cluster 3 which showed the best survival ([Figure 3B](#fig3){ref-type="fig"}; *P*\<0.001). In Cox regression, Gln--Pro PAM clusters remained independent of the standard clinicopathological parameters in predicting patient survival ([Table 3](#tbl3){ref-type="table"}; *P*=0.012).

We looked to replicate the clusters derived from the mRNA expression using the protein expression of the Gln--Pro enzymes (using the median H-scores), which similarly showed that Cluster 1 (GLS^−^/ALDH18A1^+^/PYCR1^+^) was strongly associated with ER+/HER2− high proliferation tumours, whereas Cluster 2 (GLS^+^/ALDH18A1^+^/PYCR1^+^) and Cluster 3 (GLS^+^/ALDH18A1^−^/PYCR1^−^) were associated with ER+/HER2− low proliferation and TN/HER2+ tumours, respectively ([Table 2](#tbl2){ref-type="table"}; *P*=0.001). In terms of patient outcome, Cluster 1 tumours showed the worst survival compared with Clusters 2 and 3 ([Figure 3C](#fig3){ref-type="fig"}; *P*=0.0003). In Cox regression analysis, the Glu--Pro Clusters remained independent of tumour grade, lymph node stage, tumour size, ER and HER2 status ([Table 3](#tbl3){ref-type="table"}; *P*=0.001).

c-MYC is associated with high Gln--Pro enzymes in Luminal B tumours
-------------------------------------------------------------------

*MYC* mRNA was negatively correlated with *PCYR1* (*P*=0.01) and *ALDH18A1* (*P*\<0.001) in all breast tumours, but not *GLS* ([Table 4](#tbl4){ref-type="table"}). In specific subtypes, *MYC* was positively correlated with *PYCR1* mRNA in Luminal B tumours (*P*=0.006) and negatively correlated in Luminal A tumours ([Table 4](#tbl4){ref-type="table"}; *P*\<0.001). The only other correlations between *MYC* and the Gln--Pro genes was a negative correlation with *ALDH18A1* (*P*\<0.001) in Luminal A (*P*\<0.001) and HER2+ tumours (*P*=0.002).

In terms of protein expression, MYC protein was positively associated with the individual protein expression of GLS and ALDH18A1 in all BCs, but was only associated with all three Gln--Pro enzymes in ER+/HER2− high proliferation tumours (*P*\<0.001, [Table 4](#tbl4){ref-type="table"}).

Discussion
==========

ER+/luminal tumours, which comprise the majority of BC (55--80%), remain a heterogeneous group in terms of molecular biology and patients' outcome. Despite the significant benefit of hormone therapy, a proportion of patients with luminal BC develop recurrences and die of their disease. There is therefore a clear need for improved understanding of the biology of the luminal class of BC, with subsequent translation into more effective methods of prognostic and predictive stratification of this most common form of BC.

Metabolic reprogramming in cancer including BC provides a vital role in the provision of supplementary elements including nutrients and energy, which are essential for cellular growth. Tumour cells can become reliant on Gln metabolism and become 'addicted' to this amino acid for sustained proliferation/survival. Additionally, Pro is often used as a precursor for other amino acids; therefore it is important in the synthesis of new proteins, as well as mediating redox signalling and protecting cells from oxidative stress ([@bib28]; [@bib19]).

It has also been shown that there is a major metabolic shift towards *de novo* Pro synthesis in metastatic breast tumours ([@bib30]). High levels of MYC are required to maintain this glutaminolytic phenotype, which not only sees an increase in Gln cellular uptake but also regulates Gln--Pro enzymes ([@bib33]; [@bib10]). MYC promotes the conversion of Gln to Pro by nearly 10-fold by upregulating ALDH18A1 ([@bib14]; [@bib22]).

Evidence of Gln dependence in TNBC has previously been established ([@bib13]; [@bib5]; [@bib12]; [@bib24]) but studies that address the prognostic significance of the key Gln--Pro enzymes in BC and their potential influence on Gln metabolism in the other molecular subtypes remains limited particularly in luminal BC. We have therefore investigated the expression of PYCR1, ALDH18A1 and GLS at the genomic, transcriptomic and proteomic level, and the impact of MYC on their expression, utilising a large number of breast tumours in order to better understand the potential role of this regulatory axis in BC and its molecular subtypes, particularly in the luminal tumours.

Overexpression of ALDH18A1 increases Pro levels and lowers reactive oxygen species, as well as increasing cell survival. The increase in Pro has been linked to protect cells against hydrogen peroxide-induced cell death, as well as carcinogenic stressors; therefore promoting tumour growth and proliferation ([@bib18]). In line with this, we show that high ALDH18A1 confers a poor prognosis in Luminal B tumours. Inhibition of ALDH18A1 in melanoma significantly disrupts Pro synthesis limiting cellular metabolism and decreasing cell viability, tumour growth and protein synthesis ([@bib22]; [@bib16]). Knockdown or inhibition of ALDH18A1 in Luminal B tumours could therefore potentially lead to a benefit in therapeutic targeting of this enzyme.

PYCR1 is frequently overexpressed in many cancer types ([@bib19]); in particular breast, pancreatic and ovarian cancer ([@bib26]; [@bib28]). In meta-analysis, *PYCR1* mRNA is highly expressed in the more aggressive BC subtypes, in addition to its protein in a small number of BC cases ([@bib9]). While we show similar results for mRNA in the METABRIC data set, we were unable to confirm the translation into similarly high protein expression in TNBC and HER2+ BC nor its association with patient outcome. However, we do show that Luminal B have a high copy number gain of *PYCR1* and consequently supports a role in this poor prognostic group of tumours. In prostate cancer, knockdown of *PYCR1* results in the inhibition of cell proliferation via cell cycle arrest and enhanced apoptosis ([@bib35]) although the effect on BC cells, particularly Luminal B tumours remains to be determined.

Levels and activity of GLS are significantly increased in TNBC and HER2+ BC cell lines due to their propensity for Gln dependence ([@bib32]; [@bib12]; [@bib24]) which we here confirm *in vivo*. However, we further demonstrate that GLS predicts a better outcome in HER2+ tumours and selective GLS inhibitors, such as CB-839 which blocks Gln consumption and reduces subsequent glutamate-derived metabolic intermediates, is likely to have limited use in these patients ([@bib12]).

Protein analysis also revealed that PYCR1 and ALDH18A1 are significantly associated with the MYC oncogene. This coincides with a plethora of studies, which have shown that the MYC oncogene reprograms cell metabolism and causes an upregulation of genes involved in cancer ([@bib22]; [@bib20]; [@bib27]). Multiple studies have also supported the findings in this study, as the *MYC* oncogene has resulted in an increased expression of PYCR1 and ALDH18A1 to drive Pro production; alongside fuelling the Gln and MYC addiction that cancer cells exhibit ([@bib33]; [@bib20]; [@bib28]).

It is thought that the *MYC* gene interacts with these enzymes by amplifying the existing transcriptional signalling of the gene leading to an increase in mRNA. MYC then drives the translation of mRNA in order to increase protein levels of the enzymes ([@bib26]; [@bib20]). Interestingly, studies by Wei Liu *et al* have shown that downregulating the MYC oncogene with siRNAs not only reduced the conversion of Gln to Pro but also resulted in reduced mRNA and protein expression of ALDH18A1 and PYCR1 [@bib22], [@bib21]). Silencing MYC results in a reduction of cell proliferation and induction of apoptosis; as well as decreasing levels of PYCR1 and ALDH18A1 directly ([@bib8]; [@bib22]) and targeting all three enzymes led to the substantial reduction in Pro production ([@bib22]).

Our observational findings of the Gln--Pro enzymes and their differing associations with MYC within the subgroups of BC further support the many functions of MYC within glutaminolysis. We have previously shown that MYC is potentially driving glucose metabolism in ER-negative tumours and translational function in ER-positive tumours ([@bib11]), and we further show in this study that MYC is likely driving the conversion of Gln to Pro within Luminal B tumours. Pro metabolism has a functional role in redox regulation and the conversion of Gln to Pro could be one mechanism, where this balance can be achieved, especially in the highly proliferative Luminal B tumours, which show increased metabolic rates resulting in the accumulation of ROS ([@bib3]).

In this study, we have shown that the Gln--Pro enzymes are highly expressed in a subset of ER+ tumours that have high proliferation, that is, Luminal B tumours, and are related with poor patient outcome in this group, suggesting that expression of these enzymes are regulated and driven by alternative mechanisms within the different molecular subtypes of BC and hence the pathways utilised for cell metabolism will also differ. It was also interesting to observe the difference in gene and protein expression of these enzymes within the ER+/HER2− low proliferation tumours and TNBC/HER2+ tumours. This could have arisen due to the definitions used between mRNA (PAM50) and protein (ER plus Ki67 expression). It might also reflect the differences in transcription and translational modifications.

The high expression of the Gln--Pro regulatory axis in Luminal B tumours is perhaps not unsurprising, as they will have heavier demands of nutrients and energy essential for cell survival and proliferation compared with Luminal A tumours and it is known that tumours will alter their metabolic profiles to meet the needs for their growth and proliferation. This is supported by a study carried out by [@bib17] in which differential expression patterns of Gln metabolism-related proteins were identified according to the molecular subtype of BC, with HER2+ tumours displaying highest Gln metabolic activity and higher MYC amplification and Luminal B tumours displaying higher Gln metabolic activity than Luminal A tumours.

We further show that within the highly proliferative Luminal B tumours, high expression of the Gln--Pro enzymes are all significantly associated with MYC, suggesting that it is the driving force behind the metabolic status for this subclass of BC.

Therefore, we believe that continued refinement in understanding of the biological diversity of BC, particularly the Luminal B class, with linked development of classification strategies suitable for routine clinical use are essential to achieve a personalised approach to BC management. Further investigation of Gln metabolism using a variety of *in vitro* functional assays are therefore essential to assess its the potential therapeutic value in the highly proliferative aggressive subclass of ER+Luminal B BC.
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![**Schematic representation of the enzymes involved in the glutamine regulatory axis.**](bjc2017387f1){#fig1}

![**Gln--Pro enzyme mRNA and protein expression in breast cancer molecular subtypes.** (**A**) PYCR1 mRNA expression; (**B**) PYCR1 protein expression; (**C**) ALDH18A1 mRNA expression; (**D**) ALDH18A1 protein expression; (**E**) GLS mRNA expression; (**F**) GLS protein expression. IHC = immunohistochemistry](bjc2017387f2){#fig2}

![**Glu-Pro enzyme cluster analysis in breast cancer.** Boxplots for (**A**) mRNA clusters and (**B**) protein clusters. Patient outcome for (**C**) mRNA clusters and (**D**) protein clusters.](bjc2017387f3){#fig3}

###### Gln--Pro enzymes and breast cancer molecular subtypes

              **PYCR1**    **ALDH18A1**   **GLS**                                                                                            
  ----------- ------------ -------------- ------------------------------ ------------ ---------- ------------------- ------------ ---------- ------------------------------
  **PAM50**                                                                                                                                  
  Luminal A   649 (92.3)   54 (7.7)                                      704 (98.9)   8 (1.1)                        708 (99.2)   6 (0.8)     
  Luminal B   354 (75.3)   116 (24.7)                                    466 (96.1)   19 (3.9)                       470 (98.3)   8 (1.7)     
  Basal       272 (83.4)   54 (16.6)      89.3 (**1.9 × 10**^**−18**^)   308 (94.2)   19 (5.8)   22.4 (**0.0002**)   303 (92.7)   24 (7.3)   49.5 (**4.7 × 10**^**−10**^)
  HER2        211 (89.8)   24 (10.2)                                     231 (97.9)   5 (2.1)                        229 (95.8)   10 (4.2)    
  Normal      184 (95.3)   9 (4.7)                                       196 (98.5)   3 (1.5)                        196 (100)    0           

Abbreviations: Gln=glutamine; GLS=glutaminase; PAM=partitioning around medoids; Pro=proline; PYCR1=pyrroline-5-carboxylate reductase 1. Bold values are significant *P* values.

###### Gln--Pro clusters in breast cancer molecular subtypes

                                 **Cluster 1** ***n*** **(%)**   **Cluster 2** ***n*** **(%)**   **Cluster 3** ***n*** **(%)**   ***χ***^**2**^ (***P*****-value)**
  ------------------------------ ------------------------------- ------------------------------- ------------------------------- ------------------------------------
  **mRNA**                                                                                                                       
  Luminal A                      174 (24.2)                      242 (33.7)                      302 (42.1)                       
  Luminal B                      214 (43.9)                      133 (27.3)                      141 (28.9)                       
  Basal                          91 (27.7)                       148 (45.0)                      90 (27.4)                       177.5 (**3.7 × 10**^**−34**^)
  HER2                           95 (39.6)                       110 (45.8)                      35 (14.6)                        
  Normal                         23 (11.6)                       60 (30.2)                       116 (58.3)                       
  **Protein**                                                                                                                    
  ER+/HER2− low proliferation    8 (34.8)                        10 (43.5)                       5 (21.7)                         
  ER+/HER2− high proliferation   19 (48.7)                       8 (20.5)                        12 (30.8)                       23.8 (**0.001**)
  Triple negative                1 (2.8)                         13 (36.1)                       22 (61.1)                        
  HER2+                          4 (28.6)                        4 (28.6)                        6 (42.9)                         

Abbreviations: Gln=glutamine; GLS=glutaminase; mRNA=messenger RNA; Pro=proline; PYCR1=pyrroline-5-carboxylate reductase 1. Bold values are significant *P* values.

###### Gln--Pro clusters and patient outcome

  **Parameter**        **mRNA hazard ratio (95% CI)**  ***P*****-value**    **Protein hazard ratio (95% CI)**  ***P*****-value**
  ------------------- -------------------------------- ------------------- ----------------------------------- -------------------
  Grade                      1.24 (1.05--1.47)         0.012                        1.22 (0.71--2.09)          0.466
  Lymph node stage           1.83 (1.62--2.06)         3.9 × 10^−23^                2.23 (1.24--4.03)          **0.008**
  Size                       1.58 (1.26--1.97)         0.00008                      0.89 (0.46--1.72)          0.731
  ER                         1.12 (1.01--1.25)         0.035                        1.07 (0.48--2.38)          0.878
  HER2                       0.84 (0.75--0.95)         0.004                        1.79 (0.74--4.36)          0.198
  Gln--Pro clusters          0.86 (0.76--0.97)         0.012                        0.46 (0.29--0.75)          **0.001**

Abbreviations: CI=confidence interval; Gln=glutamine; mRNA=messenger RNA; Pro=proline. Bold values are significant *P* values.

###### Gln--Pro enzymes and MYC expression in breast cancer molecular subtypes

                                        **PYCR1**                **MYC ALDH18A1**                **GLS**
  ------------------------------ ----------------------- -------------------------------- ---------------------
  **mRNA**                                                                                
  All cases                        −0.058 (**0.010**)     −0.221 (**2.3 × 10**^**−23**^)      0.038 (0.092)
  PAM50                                                                                              
   Luminal A                       −0.133 (**0.0003**)    −0.339 (**9.8 × 10**^**−21**^)     −0.017 (0.659)
   Luminal B                        0.124 (**0.006**)             −0.070 (0.123)              0.052 (0.248)
   Basal                              0.094 (0.088)               0.023 (0.677)              −0.072 (0.193)
   HER2                               0.030 (0.646)             −0.201 (**0.002**)            0.026 (0.284)
   Normal                         −0.335 (**0.000001**)   −0.395 (**7.5 × 10**^**−9**^)     −.148 (**0.037**)
  Protein                                                                                            
   All cases                         −0.011 (0.772)       0.394 (**1.8 × 10**^**−33**^)    0.148 (**0.00002**)
  **IHC molecular classes**                                                               
  ER+/HER2− low proliferation       0.166 (**0.048**)           0.253 (**0.001**)             0.124 (0.111)
  ER+/HER2− high proliferation      0.156 (**0.013**)           0.221 (**0.0001**)          0.145 (**0.015**)
  Triple negative                     0.149 (0.074)        0.378 (**3.9 × 10**^**−7**^)    0.292 (**0.0003**)
  HER2+                              −0.060 (0.551)        0.492 (**2.8 × 10**^**−8**^)       0.094 (0.329)

Abbreviations: ER=oestrogen receptor; Gln=glutamine; GLS=glutaminase; IHC=immunohistochemistry; mRNA=messenger RNA; PAM=partitioning around medoids; Pro=proline; PYCR1=pyrroline-5-carboxylate reductase 1. Bold values are significant *P* values.
